This is the authors' abstract. We don't add key points for this paper.
Background: Long-term albumin (LTA) therapy is a potential disease-modifying strategy for advanced liver disease. Randomized trials and real-world studies suggest that LTA improved survival and reduced liver-related complications. LTA use in Asia remains heterogeneous reflecting disparities in patient characteristics, healthcare systems, and treatment access. This study evaluated clinical rationale, therapeutic strategies, and outcomes of LTA in advanced liver disease across five tertiary centers in Asia. An expert panel was convened to discuss the cases, current practices and consensus development of LTA recommendations.Methods: Eight cases from Indonesia, India, and Malaysia, with decompensated cirrhosis who received LTA for ≥3 months were discussed. Each case was analyzed for therapeutic rationale, safety, and outcomes. Panelists completed pre-meeting survey, followed by structured in-person discussion.Results: Patients had varied etiologies of cirrhosis, complications, and baseline serum albumin levels generally below 3.0 g/dL, except one hepatitis B virus (HBV)-related cirrhosis with 3.1 g/dL. LTA regimen ranged from fixed dosing (60 g/week loading followed by 20–40 g/week maintenance) to individualized titration based on clinical response and serum albumin level; one patient with HBV-cirrhosis received 25 g/month with clinical benefit. LTA increased serum albumin, reduced paracentesis frequency, and improved renal function in selected case. Reductions in ascites burden or paracentesis requirement were reported in several patients, whereas one patient with polycystic liver disease continued to require twice-weekly paracentesis. Quality-of-life scores improved during follow-up in two patients with concomitant metastatic hepatocellular carcinoma (HCC). One patient experienced two episodes of post-infusion dyspnea suggestive of transient fluid overload following rapid albumin administration.Conclusions: This study provides real-world insights into patient selection, dosing strategies, and observed clinical courses and outcomes of LTA use in routine clinical practice. Given the small sample size and descriptive nature of the study, the findings should be interpreted cautiously and are hypothesis-generating rather than confirmatory. Further prospective studies and real-world evaluations are needed to better define the role of LTA in Asian population.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kulkarni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: